CLINICAL_TRIALS
trial_result
· 2020-05-14
Clinical Trial Update: Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) [Phase 2]
Summary
Phase 2 dose-response study of EMA401 in post-herpetic neuralgia was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Post-herpetic Neuralgia | Phase 2 | Status: TERMINATED | Results posted: 2020-05-14